Cyclacel's Cancer Drug Gets Fda Orphan Status: Pwrm, Siga, & Cycc

Share:    

POWER 3 MEDICAL PRODUCTS (OTC BB: PWRM.OB)

Last: $0.036

PWRM is now being traded and sold for $0.036 cents a share. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. PWRM deserves to be watched very closely! A breakout could be an indicator of possible momentum.

PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops, to cover:
Share:    

Processes - The manner in which the discoveries are made and tests developed

Discoveries - Protein disease footprints,

Products - Early detection tests, Biomarkers, and Drug Targets

The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance:

The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance.

PWRM is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.

** THE INTERNATIONAL CONGRESS OF ALZHEIMERS DISEASE ACCEPTS FOUR SCIENTIFIC PRESENTATIONS BY PWRM **

Four abstracts were accepted for presentation to the annual meeting of the International Congress of Alzheimers Disease on July 12, 2010 in Honolulu, Hawaii. The presentations will cover results from protein biomarker discovery, drug response, test development, and ongoing clinical validation trials of the PWRMs NuroPro AD biomarkers and blood test for Alzheimers disease.

The four studies to be presented involve a total of 154 Alzheimers disease patients and 91 Parkinsons disease patients, as well as 210 age-matched normal control individuals and 173 disease control individuals.

- According to recent estimates, as many as 2.4 million to 4.5 million Americans have Alzheimers disease (AD). Unless the disease can be effectively treated or prevented, the number of people with AD will increase significantly if current population trends continue. Thats because the risk of AD increases with age, and the U.S. population is aging. The number of people age 65 and older is expected to grow from 39 million in 2008 to 72 million in 2030, and the number of people with AD doubles for every 5-year interval beyond age 65. (Source: CLICK HERE)

More about PWRM at www.power3medical.com

________________________________________________

SIGA Technologies Inc. (NasdaqGM: SIGA)

Last: $7.61

SIGA, a bio-defense company, engages in the discovery, development, and commercialization of products for use in defense against biological warfare agents comprising smallpox and arenaviruses. It also involves in the discovery and development of other novel anti-infectives and antibiotics for the prevention and treatment of serious infectious diseases.

SIGA reported the successful completion of its fourth human clinical trial, supporting the safety and tolerability of the anticipated clinical dose of ST-246(R), SIGAs lead smallpox antiviral drug candidate. Analyses of the trials results are consistent with findings from previous studies of ST-246 and together show that the drug will likely be found to be a safe and well-tolerated therapeutic for the treatment of orthopoxvirus infections.

More about SIGA at www.siga.com

________________________________________________

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP)

Last: $1.63

Recent News: Cyclacel's cancer drug gets FDA orphan status

Cyclacel Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Cyclacels strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.

Applying its core strength in cell cycle biology, Cyclacel is advancing a deep pipeline of small molecule drugs designed to stop uncontrolled cell division including three clinical stage compounds and several at preclinical stages. The companys founder, Sir David Lane, is a leading authority in cell cycle biology credited with the discovery of p53, one of the most commonly mutated tumor suppressor genes in patients with cancer. Cyclacels Chief Scientist, Professor David Glover, is a recognized leader in mitosis and discoverer of the aurora and polo mitotic kinase families, essential cell cycle control mechanisms that regulate cancer cell division.

*******************************************

Sign-Up For Free Stock Alerts At http://crwepicks.com/signup

*******************************************
Share:    

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEpicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations.Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)

*******************************************

by:Blayne Sheffield

POST COMMENT

Cyclacel's Cancer Drug Gets Fda Orphan Status: Pwrm, Siga, & Cycc Avandamet – One of the Most Popular Drugs to Treat Type II Diabetes Bowel cancer patients must do without life-extending drug, says Nice How Medical Malpractice Lawsuits Might Arise If Stage 4 Prostate Cancer Is Because Of Delay From Watchful Waiting Recommendation Reverse Diabetes Obviously - Reverse Diabetes With no Drugs Integrative Medicine For The Treatment Of Cancer Internal Medicine Doctor: About Diabetes Physician May Be Liable For Medical Malpractice By Not Acting According To Colon Cancer Screening Recommendations New Chemotherapy Drugs for Esophageal Cancer Medical Care For Diabetes - What Works? Physician May Be Liable For Medical Malpractice By Not Acting According To Colon Cancer Screening Re I Did Not Know Book on Drug Abuse-Addictions on Cocaine-Heroine-Drug Addict heart Stopped 11 Minutes Personalised Medicine, The Next Frontier In Lung Cancer